MSD Innovation Factory is looking for digital solutions for anaesthesiologists

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation room) or their team building with surgeons. As a leading pharmaceutical company, MSD is aware of the need to incorporate innovation to deliver the best possible value to healthcare professionals, patients and customers. And that is the MSD Innovation Factory, where three out of the seven finalists (one per challenge) will get the top prize: up to $20,000 each to develop and locally launch the solution.

Co-create with a pharma and go together for unmet needs

MSD is having difficulty to reach anaesthesiologists to share the benefits of using Deep Block (DB) until the end of operations. Deep Block improves surgical conditions as it decreases the movement of the muscles and increases the volume at the operation area.

The main reason for not reaching them is their busy workload and the time spent at operation rooms, where MSD representatives cannot enter. There’s an opportunity for solutions oriented to education, e.g. while at the operating room, communication and team building with surgeons.

Worldwide participants are welcome to apply proposing solutions that will be implemented first in Turkey. The finalist of this challenge will have the opportunity to improve the proposal in collaboration with the local MSD team that proposed the challenge.

Find all the info about the anaesthesiologists challenge: https://www.msdinnovationfactory.com/challenges/anestouch/

Do you have a solution? Apply now!
www.msdinnovationfactory.com

How MSD Innovation Factory works

The innovation factory initiative aims to give support to the companies that come up with the best ideas to solve one of the 7 challenges identified in the EEMEA Region (Eastern Europe, Middle East and Africa) by local MSD teams.

The selection is done in four steps:

  • Solutions submitted before 31st October are reviewed by the challenge owners (the local MSD teams).
  • Each country will select the best solution for its proposed challenge.
  • During co-creation sessions the selected company and the local MSD team will work together in an improved proposal to be jointly presented in a Final event.
  • At the Final event in January 2018, the 7 finalists will pitch their solution in front of a senior jury from MSD. The jury will award 3 winners.

The prizes

Each of the 3 winners will receive the following:
  • Up to $20,000 to pilot their solution in the challenge-related local market.
  • Support from MSD local team to connect with the local ecosystem (eg. medical professional associations), deal with potential regulatory issues and disseminate leveraging MSD local channels. It will also contribute with expertise and business know-how.
  • If the local launch is a success after 12 months, its outcomes will be globally shared within MSD to investigate further implementation beyond the initial market.

All 7 finalists will get a 500€ grant to cover travel expenses to attend the Final event in Istanbul, and the opportunity to optimize their proposal in collaboration with the local MSD team that proposed the challenge. They will also receive visibility through the initiative communication channels.

MSD is a global healthcare company with a 125-year history committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

Applications until 31 October

Do you have a solution? Apply now!
www.msdinnovationfactory.com

Most Popular Now

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

FDA accepts regulatory submission for Lynparza in …

AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Three of the most deadly cancers get critical fund…

Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the de...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]